Liabilities and Equity of VBI Vaccines Inc/BC from 31 Dec 2015 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
VBI Vaccines Inc/BC quarterly Liabilities and Equity in USD history and change rate from 31 Dec 2015 to 31 Mar 2024.
  • VBI Vaccines Inc/BC Liabilities and Equity for the quarter ending 31 Mar 2024 was $75,443,000, a 41% decline year-over-year.
Source SEC data
View on sec.gov
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Change (%)

VBI Vaccines Inc/BC Quarterly Liabilities and Equity (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $75,443,000 -$53,018,000 -41% 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $86,951,000 -$68,135,000 -44% 31 Dec 2023 10-Q 15 May 2024 2024 Q1
Q3 2023 $100,784,000 -$71,226,000 -41% 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $88,322,000 -$83,839,000 -49% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $128,461,000 -$65,545,000 -34% 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $155,086,000 -$55,190,000 -26% 31 Dec 2022 10-K 16 Apr 2024 2023 FY
Q3 2022 $172,010,000 -$52,218,000 -23% 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $172,161,000 -$52,471,000 -23% 30 Jun 2022 10-Q 08 Aug 2022 2022 Q2
Q1 2022 $194,006,000 -$28,890,000 -13% 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 $210,276,000 +$904,000 +0.43% 31 Dec 2021 10-K 13 Mar 2023 2022 FY
Q3 2021 $224,228,000 +$24,674,000 +12% 30 Sep 2021 10-Q 08 Nov 2021 2021 Q3
Q2 2021 $224,632,000 +$63,445,000 +39% 30 Jun 2021 10-Q 02 Aug 2021 2021 Q2
Q1 2021 $222,896,000 +$115,662,000 +108% 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $209,372,000 +$87,171,000 +71% 31 Dec 2020 10-K 07 Mar 2022 2021 FY
Q3 2020 $199,554,000 +$67,618,000 +51% 30 Sep 2020 10-Q 02 Nov 2020 2020 Q3
Q2 2020 $161,187,000 +$46,538,000 +41% 30 Jun 2020 10-Q 31 Jul 2020 2020 Q2
Q1 2020 $107,234,000 -$19,009,000 -15% 31 Mar 2020 10-Q 06 May 2020 2020 Q1
Q4 2019 $122,201,000 -$15,404,000 -11% 31 Dec 2019 10-K 02 Mar 2021 2020 FY
Q3 2019 $131,936,000 +$23,112,000 +21% 30 Sep 2019 10-Q 06 Nov 2019 2019 Q3
Q2 2019 $114,649,000 -$5,040,000 -4.2% 30 Jun 2019 10-Q 09 Aug 2019 2019 Q2
Q1 2019 $126,243,000 -$8,578,000 -6.4% 31 Mar 2019 10-Q 01 May 2019 2019 Q1
Q4 2018 $137,605,000 -$8,051,000 -5.5% 31 Dec 2018 10-K 05 Mar 2020 2019 FY
Q3 2018 $108,824,000 +$20,344,000 +23% 30 Sep 2018 10-Q 09 Nov 2018 2018 Q3
Q2 2018 $119,689,000 +$27,694,000 +30% 30 Jun 2018 10-Q 26 Jul 2018 2018 Q2
Q1 2018 $134,821,000 +$37,832,000 +39% 31 Mar 2018 10-Q 01 May 2018 2018 Q1
Q4 2017 $145,656,000 +$40,902,000 +39% 31 Dec 2017 10-K 25 Feb 2019 2018 FY
Q3 2017 $88,480,000 30 Sep 2017 10-Q 13 Nov 2017 2017 Q3
Q2 2017 $91,995,000 30 Jun 2017 10-Q 31 Jul 2017 2017 Q2
Q1 2017 $96,989,000 31 Mar 2017 10-Q 15 May 2017 2017 Q1
Q4 2016 $104,754,000 +$87,709,000 +515% 31 Dec 2016 10-K 26 Feb 2018 2017 FY
Q4 2015 $17,045,000 31 Dec 2015 10-K 20 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.